The advent of PCSK9 inhibitors marks a significant advancement in pharmacological lipid-lowering therapy, particularly for the treatment of primary hypercholesterolemia and the prevention of cardiovascular events. The gene discussed is PCSK9; the disease is Hypercholesterolemia.